Velo3D 2025 Financial Performance Review
Velo3D, Inc. is an additive manufacturing technology company that transforms aerospace and defense supply chains with metal 3D printing. Full-year...
ADVERTISEMENT
Earnings
Fennec Pharmaceuticals 2025 Financial Update
Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company committed to the fight against ototoxicity in cancer patients. The company recently...
Core & Main, Inc. (CNM) Q4 Earnings: Misses on EPS, Revenue Recap
Significant earnings miss. Core & Main, Inc. (CNM) reported Q4 2025 adjusted earnings of $0.52 per share, falling well short…
Avalo Therapeutics 2025 Financial Review
Avalo Therapeutics is a clinical-stage biotechnology company dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases. The company’s lead asset,...
WeRide Inc. 2025 Financial Performance Review
WeRide Inc. is a global leader in autonomous driving technology and the first publicly traded robotaxi company. For the full...
Surrozen 2025 Financial Results Review
Surrozen is a biotechnology company developing targeted therapeutics that harness Wnt signaling to address sight-threatening ophthalmic conditions. For the full...
PPHC Q4 and FY 2025 Financial Review
Public Policy Holding Company, Inc. (PPHC) is a global strategic communications provider offering advisory services across Government Relations, Corporate Communications,...
Cabaletta Bio Q4 and FY 2025 Financial Review
Cabaletta Bio is a late-stage clinical biotechnology company focused on developing targeted cell therapies specifically for patients with autoimmune diseases....
Arbutus Biopharma 2025 Financial Review
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company focused on infectious diseases. For the year ended December 31, 2025, Arbutus...
Sutro Biopharma 2025 Financial Review
Sutro Biopharma is a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs). For the year ended December...